25 September 2023

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Group")

Director Dealings

Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, announces that the Board has approved an 18-month extension of the timeline in which Mr Jeremy Randall may exercise the 483,333 share options granted to him on 5 November 2013 such that these options will now lapse on 5 May 2025 rather than 5 November 2023.

As at the time of this announcement, Mr Randall owns 1.65% of the issued share capital of VLG and holds 2,483,333 share options.

For further information, please contact:

Venture Life Group PLC                                                                                                    +44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

Cavendish Securities plc (Nomad and Joint Broker)                                            +44 (0) 20 7720 0500

Stephen Keys / Camilla Hume (Corporate Finance)

Michael Johnson (Sales)

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Active range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.